A BILL 
To amend title XVIII of the Social Security Act to require 
drug manufacturers to pay a Medicare part B rebate 
for certain drugs if the price of such drugs increases 
faster than inflation. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Freedom from Price 
4
Gouging Act’’. 
5
23:44 Jun 02, 2021
H2706
2 
•HR 2706 IH
SEC. 2. MEDICARE PART B PRESCRIPTION DRUG INFLA-
1
TION REBATE BY MANUFACTURERS. 
2
(a) IN GENERAL.—Section 1834 of the Social Secu-
3
rity Act (42 U.S.C. 1395m) is amended by adding at the 
4
end the following new subsection: 
5
‘‘(z) REBATE
BY MANUFACTURERS
FOR SINGLE 
6
SOURCE DRUGS WITH PRICES INCREASING FASTER 
7
THAN INFLATION.— 
8
‘‘(1) REQUIREMENTS.— 
9
‘‘(A) SECRETARIAL PROVISION OF INFOR-
10
MATION.—Not later than 6 months after the 
11
end of each calendar quarter beginning on or 
12
after July 1, 2022, the Secretary shall, for each 
13
part B rebatable drug, report to each manufac-
14
turer of such part B rebatable drug the fol-
15
lowing for such calendar quarter: 
16
‘‘(i) Information on the total number 
17
of billing units described in subparagraph 
18
(A)(i) of paragraph (3) with respect to 
19
such drug and calendar quarter. 
20
‘‘(ii) Information on the amount (if 
21
any) of the excess average sales price in-
22
crease described in subparagraph (A)(ii) of 
23
such paragraph for such drug and calendar 
24
quarter. 
25
23:44 Jun 02, 2021
H2706
3 
•HR 2706 IH
‘‘(iii) The rebate amount specified 
1
under such paragraph for such part B 
2
rebatable drug and calendar quarter. 
3
‘‘(B) MANUFACTURER
REQUIREMENT.— 
4
For each calendar quarter beginning on or after 
5
July 1, 2022, the manufacturer of a part B 
6
rebatable drug shall, for such drug, not later 
7
than 30 days after the date of receipt from the 
8
Secretary of the information described in sub-
9
paragraph (A) for such calendar quarter, pro-
10
vide to the Secretary a rebate that is equal to 
11
the amount specified in paragraph (3) for such 
12
drug for such calendar quarter. 
13
‘‘(2) PART B REBATABLE DRUG DEFINED.— 
14
‘‘(A) IN GENERAL.—In this subsection, the 
15
term ‘part B rebatable drug’ means a single 
16
source drug or biological (as defined in sub-
17
paragraph (D) of section 1847A(c)(6)), includ-
18
ing a biosimilar biological product (as defined 
19
in subparagraph (H) of such section), paid for 
20
under this part, except such term shall not in-
21
clude such a drug or biological— 
22
‘‘(i) if the average total allowed 
23
charges for a year per individual that uses 
24
such a drug or biological, as determined by 
25
23:44 Jun 02, 2021
H2706
4 
•HR 2706 IH
the Secretary, are less than, subject to 
1
subparagraph (B), $100; or 
2
‘‘(ii) that is a vaccine described in 
3
subparagraph (A) or (B) of section 
4
1861(s)(10). 
5
‘‘(B) INCREASE.—The dollar amount ap-
6
plied under subparagraph (A)(i)— 
7
‘‘(i) for 2023, shall be the dollar 
8
amount specified under such subparagraph 
9
for 2022, increased by the percentage in-
10
crease in the consumer price index for all 
11
urban consumers (United States city aver-
12
age) as of the first quarter of the previous 
13
year; and 
14
‘‘(ii) for a subsequent year, shall be 
15
the dollar amount specified in this clause 
16
(or clause (i)) for the previous year, in-
17
creased by the percentage increase in the 
18
consumer price index for all urban con-
19
sumers (United States city average) as of 
20
the first quarter of the previous year. 
21
Any dollar amount specified under this sub-
22
paragraph that is not a multiple of $10 shall be 
23
rounded to the nearest multiple of $10. 
24
‘‘(3) REBATE AMOUNT.— 
25
23:44 Jun 02, 2021
H2706
5 
•HR 2706 IH
‘‘(A) IN GENERAL.—For purposes of para-
1
graph (1)(B), the amount specified in this para-
2
graph for a part B rebatable drug assigned to 
3
a billing and payment code for a calendar quar-
4
ter is, subject to paragraph (4), the amount 
5
equal to the product of— 
6
‘‘(i) subject to subparagraph (B), the 
7
total number of billing units, as described 
8
in section 1847A(b)(6)(B), for such part B 
9
rebatable drug furnished under this part 
10
during the calendar quarter; and 
11
‘‘(ii) the amount (if any) by which— 
12
‘‘(I) the payment amount under 
13
subparagraph (B) or (C) of section 
14
1847A(b)(1), as applicable, for such 
15
part B rebatable drug during the cal-
16
endar quarter; exceeds 
17
‘‘(II) the inflation-adjusted pay-
18
ment amount determined under sub-
19
paragraph (C) for such part B 
20
rebatable drug during the calendar 
21
quarter. 
22
‘‘(B) EXCLUDED UNITS.—For purposes of 
23
subparagraph (A)(i), the total number of billing 
24
23:44 Jun 02, 2021
H2706
6 
•HR 2706 IH
units for part B rebatable drugs furnished dur-
1
ing a calendar quarter shall not include— 
2
‘‘(i) units packaged into the payment 
3
for a related procedure or service under 
4
section 1833(t) or under section 1833(i) 
5
(instead of separately payable under such 
6
respective section); 
7
‘‘(ii) units included under the single 
8
payment system for renal dialysis services 
9
under section 1881(b)(14); or 
10
‘‘(iii) units of a part B rebatable drug 
11
of a manufacturer that is furnished to an 
12
individual, if such manufacturer, with re-
13
spect to the furnishing of such units of 
14
such drug, provides for discounts under 
15
section 340B of the Public Health Service 
16
Act or for rebates under section 1927. 
17
‘‘(C) DETERMINATION OF INFLATION-AD-
18
JUSTED PAYMENT AMOUNT.—The inflation-ad-
19
justed payment amount determined under this 
20
subparagraph for a part B rebatable drug for 
21
a calendar quarter is— 
22
‘‘(i) the payment amount for the bill-
23
ing and payment code for such drug in the 
24
23:44 Jun 02, 2021
H2706
7 
•HR 2706 IH
payment amount benchmark quarter (as 
1
defined in subparagraph (D)); increased by 
2
‘‘(ii) the percentage by which the re-
3
bate period CPI–U (as defined in subpara-
4
graph (F)) for the calendar quarter ex-
5
ceeds the benchmark period CPI–U (as de-
6
fined in subparagraph (E)). 
7
‘‘(D) 
PAYMENT
AMOUNT
BENCHMARK 
8
QUARTER.—The term ‘payment amount bench-
9
mark quarter’ means the calendar quarter be-
10
ginning January 1, 2016. 
11
‘‘(E) BENCHMARK
PERIOD
CPI–U.—The 
12
term ‘benchmark period CPI–U’ means the con-
13
sumer price index for all urban consumers 
14
(United States city average) for July 2015. 
15
‘‘(F) REBATE PERIOD CPI–U.—The term 
16
‘rebate period CPI–U’ means, with respect to a 
17
calendar quarter described in subparagraph 
18
(C), the greater of the benchmark period CPI– 
19
U and the consumer price index for all urban 
20
consumers (United States city average) for the 
21
first month of the calendar quarter that is two 
22
calendar quarters prior to such described cal-
23
endar quarter. 
24
23:44 Jun 02, 2021
H2706
8 
•HR 2706 IH
‘‘(4) SPECIAL TREATMENT OF CERTAIN DRUGS 
1
AND EXEMPTION.— 
2
‘‘(A) SUBSEQUENTLY APPROVED DRUGS.— 
3
Subject to subparagraph (B), in the case of a 
4
part B rebatable drug first approved by the 
5
Food and Drug Administration after July 1, 
6
2015, clause (i) of paragraph (3)(C) shall be 
7
applied as if the term ‘payment amount bench-
8
mark quarter’ were defined under paragraph 
9
(3)(D) as the third full calendar quarter after 
10
the day on which the drug was first marketed 
11
and clause (ii) of paragraph (3)(C) shall be ap-
12
plied as if the term ‘benchmark period CPI–U’ 
13
were defined under paragraph (3)(E) as if the 
14
reference to ‘July 2015’ under such paragraph 
15
were a reference to ‘the first month of the first 
16
full calendar quarter after the day on which the 
17
drug was first marketed’. 
18
‘‘(B) TIMELINE
FOR
PROVISION
OF
RE-
19
BATES FOR NEW DRUGS.—In the case of a part 
20
B rebatable drug first approved by the Food 
21
and Drug Administration after July 1, 2015, 
22
clause (i) of paragraph (1)(B) shall be applied 
23
as if the reference to ‘July 1, 2022’ under such 
24
paragraph were a reference to the later of the 
25
23:44 Jun 02, 2021
H2706
9 
•HR 2706 IH
6th full calendar quarter after the day on which 
1
the drug was first marketed or July 1, 2022. 
2
‘‘(C) EXEMPTION FOR SHORTAGES.—The 
3
Secretary may reduce or waive the rebate under 
4
paragraph (1)(B) with respect to a part B 
5
rebatable drug that appears on the drug short-
6
age list in effect under section 506(e) of the 
7
Federal Food, Drug, and Cosmetic Act or in 
8
the case of other exigent circumstances, as de-
9
termined by the Secretary. 
10
‘‘(5) APPLICATION TO BENEFICIARY COINSUR-
11
ANCE.—In the case of a part B rebatable drug for 
12
which a rebate is payable under this subsection— 
13
‘‘(A) in computing the amount of any coin-
14
surance applicable under this title to an indi-
15
vidual with respect to such drug, the computa-
16
tion of such coinsurance shall be based on the 
17
inflation-adjusted payment amount determined 
18
under paragraph (3)(C) for such part B 
19
rebatable drug; and 
20
‘‘(B) the amount of such coinsurance is 
21
equal to 20 percent of such inflation-adjusted 
22
payment amount so determined. 
23
‘‘(6) REBATE DEPOSITS.—Amounts paid as re-
24
bates under paragraph (1)(B) shall be deposited into 
25
23:44 Jun 02, 2021
H2706
10 
•HR 2706 IH
the Federal Supplementary Medical Insurance Trust 
1
Fund established under section 1841. 
2
‘‘(7) CIVIL MONEY PENALTY.—If a manufac-
3
turer of a part B rebatable drug has failed to com-
4
ply with the requirements under paragraph (1)(B) 
5
for such drug for a calendar quarter, the manufac-
6
turer shall be subject to, in accordance with a proc-
7
ess established by the Secretary pursuant to regula-
8
tions, a civil money penalty in an amount equal to 
9
at least 125 percent of the amount specified in para-
10
graph (3) for such drug for such calendar quarter. 
11
The provisions of section 1128A (other than sub-
12
sections (a) (with respect to amounts of penalties or 
13
additional assessments) and (b)) shall apply to a 
14
civil money penalty under this paragraph in the 
15
same manner as such provisions apply to a penalty 
16
or proceeding under section 1128A(a). 
17
‘‘(8) STUDY AND REPORT.— 
18
‘‘(A) STUDY.—The Secretary shall conduct 
19
a study of the feasibility of and operational 
20
issues involved with the following: 
21
‘‘(i) Including multiple source drugs 
22
(as defined in section 1847A(c)(6)(C)) in 
23
the rebate system under this subsection. 
24
23:44 Jun 02, 2021
H2706
11 
•HR 2706 IH
‘‘(ii) Including drugs and biologicals 
1
paid for under MA plans under part C in 
2
the rebate system under this subsection. 
3
‘‘(iii) Including drugs excluded under 
4
paragraph (2)(A) and billing units of 
5
drugs excluded under paragraph (3)(B) in 
6
the rebate system under this subsection. 
7
‘‘(B) REPORT.—Not later than 3 years 
8
after the date of the enactment of this sub-
9
section, the Secretary shall submit to Congress 
10
a report on the study conducted under subpara-
11
graph (A). 
12
‘‘(9) APPLICATION
TO
MULTIPLE
SOURCE 
13
DRUGS.—The Secretary may, based on the report 
14
submitted under paragraph (8) and pursuant to 
15
rulemaking, apply the provisions of this subsection 
16
to multiple source drugs (as defined in section 
17
1847A(c)(6)(C)), including, for purposes of deter-
18
mining the rebate amount under paragraph (3), by 
19
calculating 
manufacturer-specific 
average 
sales 
20
prices for the benchmark period and the rebate pe-
21
riod.’’. 
22
(b) AMOUNTS PAYABLE; COST-SHARING.—Section 
23
1833(a) of the Social Security Act (42 U.S.C. 1395l(a)) 
24
is amended— 
25
23:44 Jun 02, 2021
H2706
12 
•HR 2706 IH
(1) in paragraph (1)— 
1
(A) in subparagraph (S), by striking ‘‘with 
2
respect to’’ and inserting ‘‘subject to subpara-
3
graph (EE), with respect to’’; 
4
(B) by striking ‘‘and (DD)’’ and inserting 
5
‘‘(DD)’’; and 
6
(C) by inserting before the semicolon at 
7
the end the following: ‘‘, and (EE) with respect 
8
to a part B rebatable drug (as defined in para-
9
graph (2) of section 1834(z)) for which a rebate 
10
is payable under such section, the amounts paid 
11
shall be the difference between (i) the payment 
12
amount under paragraph (3)(A)(ii)(I) of such 
13
section for such drug, and (ii) 20 percent of the 
14
inflation-adjusted payment amount under para-
15
graph (3)(A)(ii)(II) of such section for such 
16
drug’’; and 
17
(2) by adding at the end of the flush left matter 
18
following paragraph (10), the following: 
19
‘‘For purposes of applying paragraph (1)(EE) and section 
20
1834(z)(5), the Secretary shall make such estimates and 
21
use such data as the Secretary determines appropriate.’’. 
22
(c) CONFORMING AMENDMENT TO PART B ASP CAL-
23
CULATION.—Section 1847A(c)(3) of the Social Security 
24
23:44 Jun 02, 2021
H2706
13 
•HR 2706 IH
Act (42 U.S.C. 1395w–3a(c)(3)) is amended by inserting 
1
‘‘or section 1834(z)’’ after ‘‘section 1927’’. 
2
Æ 
23:44 Jun 02, 2021
H2706
